| Literature DB >> 34185894 |
Efthymios Manolis1,2, Flora T Musuamba2,3, Kristin E Karlsson2,4.
Abstract
Getting the right dose regimen for children and adolescents is important but poses great scientific, practical, and ethical challenges. At the same time, the availability of data in adults is a huge advantage and needs to be used optimally when designing studies in children and analyzing pediatric data. Furthermore, the processes of maturation and growth are always key when selecting doses for children. All the above make study adaptations and model-informed approaches imperative for dose exposure-response characterization and dose selection in children. This article summarizes the experience gained in the European Medicines Agency on this topic and proposes some general guiding principles for defining objectives, study designs, and methodology tools for pediatric dose selection.Entities:
Keywords: MIDD (model-informed drug development); exposure response; modeling and simulation; pediatrics (PED); regulatory/scientific affairs (REG)
Mesh:
Substances:
Year: 2021 PMID: 34185894 DOI: 10.1002/jcph.1863
Source DB: PubMed Journal: J Clin Pharmacol ISSN: 0091-2700 Impact factor: 3.126